SOURCE: OmniComm Systems, Inc.

April 10, 2007 10:52 ET

OmniComm Systems "Inks" 10 New Electronic Data Capture (EDC) Deals in First Quarter 2007

Company Secures 4 Studies From New Customers and Adds Another 6 Studies From Existing Clients

FT. LAUDERDALE, FL -- (MARKET WIRE) -- April 10, 2007 -- OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that they have closed 10 new business deals in Q1, 2007. This new business comes from a variety of companies, including Medical Device, Biotechnology, Contract Research Organizations, Academic Medical Centers and Healthcare.

"We are very pleased with the results of our first quarter," said Steve Johnson, Sr. VP of Business Development. "We've had a good mix of new customer business with repeat business from existing clients to fuel our growth. OmniComm's dedication to delivering above and beyond what our customers expect remains a critical part of our company's mission and it's what keeps our customers coming back." Johnson added, "With our new customers, we look forward to building long-term business relationships and delivering superior EDC solutions."

2007 business deals include:


--  1 year, Phase II diabetes study with 25 sites and 210 subjects
--  3 month, Phase I cardiovascular study with 1 site and 20 subjects
--  2 month, Phase I obesity study with 2 sites and 92 subjects
--  3 month, Phase I cardiovascular study with 1 site and 20 subjects
Contract Research Organization
--  15 month, Phase II/III infectious disease study with 20 sites and 300
--  5 month, Phase I infectious disease study with 1 site and 24 subjects
Medical Device
--  5 year, Phase III cardiovascular study with 40 sites
--  72 month, Phase III cardiovascular study with 15 sites and 35 subjects
--  12 month, Phase II cardiovascular study with 6 sites and 75 subjects
--  3 month, post marketing muscle strength and endurance observational
    study with 4 sites and 60 subjects
About OmniComm

OmniComm Systems, Inc. ( provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled "The Promise of Next-Gen eClinical Trial Software" by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact